Efficacy of Probiotics as an Adjunct to Scaling and Root Planing in Periodontitis: A Randomized, Double-Blind, Placebo-Controlled Trial

This is randomized double blind placebo controlled three arm trial. individuals meeting eligibility criteria after ICF signing  will be randomly allocated to either group1 receiving on chewable probiotic tablet containing Lactobacillus reutri UBLRu-87, twice daily for 84 days. Group 2 will receive one chewable probiotic tablet containing a blend of Streptococcus salivarius UBSS-01, Lactobacillus salivarius UBLSS-22, Lactobacillus plantarum UBLP-40, Lactobacillus reuteri UBLRu-87, Bacillus coagulans, fructo-oligosaccharides, elemental zinc (from zinc citrate), vitamin D3, taken twice daily for 84 days.Group 3 will receive one chewable placebo tablet identical in appearance to the probiotic tablets, taken twice daily for 84 days.There will be total 5 visits- Visit -1 (Day -1);  Visit 2 (Day 0 -Baseline; Visit 3  (Day 28); Visit 4 (Day 56);  Visit 5 (Day 84). The primary outcome measures will be changes in probing pocket depth (PPD) and clinical attachment level (CAL) following periodontal therapy in patients with moderate to severe periodontitis and halitosis. Secondary outcome measures will include bleeding on probing (BOP), gingival index (GI), plaque index (PI), Winkel Tongue Coating Index (WTCI), and levels of volatile sulfur compounds (VSCs) associated with halitosis.